Menopause Market Size, Share & Trends Analysis Report and Growth Forecasts 2025-2030: Menopause Market Projected To Reach $24.35 Billion By 2030 With A 5.42% CAGR
Menopause Market
Dublin, July 04, 2025 (GLOBE NEWSWIRE) -- The "Menopause Market Size, Share & Trends Analysis Report by Treatment (Dietary Supplements, OTC Pharma Products), Region (NA, Europe, APAC, Latin America, MEA) with Growth Forecasts, 2025-2030" report has been added to ResearchAndMarkets.com's offering.The Menopause Market was valued at USD 17.79 billion in 2024, and is projected to reach USD 24.35 billion by 2030, rising at a CAGR of 5.42%.
The market growth is expected to be driven by factors such as rising prevalence of post-menopausal syndrome, increasing awareness regarding menopause-associated health aspects, and high adoption of women's health apps.
The market is projected to be driven by rising research supporting the benefits of dietary supplements over HRT. Many dietary supplements are available in the market that contain ingredients such as black cohosh, red clover, soy isoflavones, and amberen. Manufacturers are also involved in developing new products to address menopausal symptoms. For instance, Morphus launched several supplement products in 2023 to address some of the most pressing symptoms of menopause and perimenopause. The first product launched was FiberUs, an unflavored soluble prebiotic fiber made from guar fiber.The demand for dietary supplements and OTC pharma products increased in the post-pandemic scenario due to the delays in physician's appointments, rescheduling of hormonal replacement therapies, and the easy availability of OTC drugs from retail pharmacies and online channels. However, the market is now stabilizing due to the ease of restrictions and the increasing awareness of menopause.The surge in FDA approvals for drugs aimed at treating hot flashes and night sweats is a significant factor propelling the growth of the market. In May 2023, the FDA gave their approval for a new non-hormonal medication to address night sweats and hot flashes that are often experienced by individuals during menopause. This prescription drug, called fezolinetant, is specifically designed for those who are unable to take hormonal therapy and who are struggling with vasomotor symptoms, such as breast cancer survivors. The medication is branded under the name Veozah.Menopause Market Report Highlights
Based on treatment, the dietary supplements treatment segment dominated the market in 2024 and is expected to witness the fastest growth during the forecast period. The growth of the segment can be attributed to several factors, including the increasing geriatric population and the launch of innovative products. For instance, in April 2021, Pulmuone, a South Korea-based dietary supplement firm, introduced a product that contains soybean and hop extracts for the treatment of menopause-related symptoms
The OTC pharmaceutical products treatment segment is categorized into non-hormonal and hormonal products. Women undergoing menopause are increasingly using over-the-counter (OTC) hormone products. Major products in this segment include topical progesterone, ibuprofen, Dehydroepiandrosterone (DHEA), and melatonin
North America held the largest revenue share in 2024. There is a growing awareness about dietary requirements, which is leading to a greater demand among older women for specific nutritional needs
In January 2022, Amyris, Inc. announced that it has entered into exclusive agreements to acquire the assets of a women-founded company MenoLabs, LLC. that focuses on treating menopause symptoms, conducting research of women's health and increasing society's understanding of menopause
In January 2023, O Positiv, a women's health brand, launched the first-ever menopause gummy vitamin, providing menopausal women with a convenient and tasty way to manage their symptoms
This report addresses:
Market intelligence to enable effective decision-making
Market estimates and forecasts from 2018 to 2030
Growth opportunities and trend analyses
Segment and regional revenue forecasts for market assessment
Competition strategy and market share analysis
Product innovation listings for you to stay ahead of the curve
Why Should You Buy This Report?
Comprehensive Market Analysis: Gain detailed insights into the market across major regions and segments.
Competitive Landscape: Explore the market presence of key players.
Future Trends: Discover the pivotal trends and drivers shaping the future of the market.
Actionable Recommendations: Utilize insights to uncover new revenue streams and guide strategic business decisions.
Companies Featured The major companies featured in this Menopause market report include:
Bayer AG
Theramex
AbbVie, Inc.
Pure Encapsulations, LLC
Dr. Reddy's Laboratories Ltd.
ReNew Life Holdings Corporation
Padagis
Key Attributes:
Report Attribute
Details
No. of Pages
210
Forecast Period
2024 - 2030
Estimated Market Value (USD) in 2024
$17.79 Billion
Forecasted Market Value (USD) by 2030
$24.35 Billion
Compound Annual Growth Rate
5.4%
Regions Covered
Global
Key Topics Covered: Chapter 1. Methodology and ScopeChapter 2. Executive Summary2.1. Market Outlook2.2. Segment Outlook2.3. Competitive InsightsChapter 3. Menopause Market Variables, Trends & Scope3.1. Market Lineage Outlook3.1.1. Parent market outlook3.2. Market Dynamics3.2.1. Market driver analysis3.2.1.1. A growing number of women experiencing menopause3.2.1.2. Increasing awareness regarding the treatment of menopausal symptoms3.2.1.3. Innovation in products available for the management of Menopause3.2.1.4. Increasing research supporting the advantages of dietary supplements3.2.2. Market restraint analysis3.2.2.1. Social stigma associated with menopause and adverse effects of products3.2.2.2. Lack of well-defined regulations3.3. Qualitative Analysis Impact of COVID-19 on Menopause Market3.4. List of Products3.5. Business Environment AnalysisChapter 4. Menopause Market Segment Analysis, By Treatment, 2018-2030 (USD Million)4.1. Menopause Market: Treatment Movement Analysis and Market Share4.2. Menopause Market: Treatment Segment Dashboard4.3. Dietary Supplements4.4. OTC Pharma Products4.4.1. OTC pharma products market, 2018-2030 (USD Million)4.4.2. Hormonal Products4.4.3. Non-hormonal productsChapter 5. Region, By Treatment, 2018-2030 (USD Million)5.1. Regional Market Dashboard5.2. Regional marketplace: Key takeawaysChapter 6. Competitive Landscape6.1. Recent Developments & Impact Analysis, By Key Market Participants6.2. Company Categorization6.3. Vendor Landscape6.4. Company Profiles
For more information about this report visit https://www.researchandmarkets.com/r/bungbs
About ResearchAndMarkets.comResearchAndMarkets.com is the world's leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends.
Attachment
Menopause Market
CONTACT: CONTACT: ResearchAndMarkets.com Laura Wood,Senior Press Manager press@researchandmarkets.com For E.S.T Office Hours Call 1-917-300-0470 For U.S./ CAN Toll Free Call 1-800-526-8630 For GMT Office Hours Call +353-1-416-8900擷取數據時發生錯誤
登入存取你的投資組合
擷取數據時發生錯誤
擷取數據時發生錯誤
擷取數據時發生錯誤
擷取數據時發生錯誤
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
4 hours ago
- Yahoo
Abbott, Beta Bionics Partner to Integrate Dual Glucose-Ketone Sensor with iLet Bionic Pancreas
Abbott Laboratories (NYSE:ABT) is one of the high profit margin stocks to buy now. On June 19, Beta Bionics Inc. (NASDAQ:BBNX) announced its plan to integrate its iLet Bionic Pancreas automated insulin delivery/AID system with Abbott's future dual glucose-ketone sensor in the US. The collaboration aims to enhance real-time decision-making support for individuals with diabetes. The iLet Bionic Pancreas received FDA clearance in May 2023 and is distinguished as the first and only AID system that autonomously makes 100% of insulin dosing decisions. This eliminates the need for carb counting or manual insulin correction calculations for users, though they still need to be 'carb aware.' The system currently supports Abbott's FreeStyle Libre 3 Plus continuous glucose monitoring sensor, and the new agreement deepens the ongoing partnership between Beta Bionics and Abbott. An operating room with a doctor monitoring a patient's vital signs during surgery with a medical device. The new dual sensor is currently under development and is built on the same form factor as Abbott's FreeStyle Libre 3 Plus and will continuously monitor both glucose and ketone levels. Ketone monitoring is a crucial advancement as it can help detect early signs of diabetic ketoacidosis, which is a serious complication of diabetes. Abbott's dual glucose-ketone sensor has received FDA breakthrough device designation. Abbott Laboratories (NYSE:ABT) discovers, develops, manufactures, and sells health care products. Beta Bionics Inc. (NASDAQ:BBNX) is a commercial-stage medical device company. While we acknowledge the potential of ABT as an investment, we believe certain AI stocks offer greater upside potential and carry less downside risk. If you're looking for an extremely undervalued AI stock that also stands to benefit significantly from Trump-era tariffs and the onshoring trend, see our free report on the . READ NEXT: and . Disclosure: None. This article is originally published at Insider Monkey. Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
USA Today
8 hours ago
- USA Today
That cucumber recall? You might want to check your fridge
Salmonella infects 1.35 million people every year. One expert said recalls are the last line of defense. Does it feel like there have been lots of cucumber recalls lately? You are not wrong. The Food and Drug Administration has classified 137 potential salmonella recall reports for food products containing cucumbers in 2025, more than in any other year with available data. The Centers for Disease Control and Prevention has linked cucumbers to a current salmonella outbreak. Salmonella bacteria are a major cause of foodborne illness, infecting 1.35 million people and killing 420 people each year. Since 2012, the Food and Drug Administration has classified over 3,200 salmonella food reports, according to federal data. On average, a salmonella recall lasts nearly a year, a USA TODAY review of the FDA data found. Currently, there are 217 salmonella recall reports ongoing. You can explore the products here: The FDA has the authority to mandate a recall, but about 99% are voluntarily issued by the companies that make the products. After a recall is initiated, the agency classifies the health hazard presented by the product from Class I (a reasonable probability that the product will cause serious adverse health consequences or death) to Class III (the product is not likely to cause adverse health consequences). About 44% of food recall reports have been classified as Class I. On the other hand, 80% of salmonella food reports are classified as Class I. Most people get infected with salmonella by eating contaminated food like raw or undercooked meat, poultry, eggs, raw or unpasteurized milk and other dairy products, and produce. According to the CDC, 1 in 25 packages of chicken in the grocery store is contaminated with salmonella. Department of Human and Health Services Secretary Robert Kennedy Jr. is among the many promoting raw milk, but experts caution against it. 'We have people whose families have had children and parents and others sickened after drinking raw milk,' said Sandra Eskin, CEO at the nonprofit Stop Foodborne Illness. 'It has salmonella in it, it can have E. coli, and it can have any number of pathogens. That's why they invented pasteurization.' Warmer weather can also create ideal conditions for the bacteria to grow, so it's recommended to refrigerate perishable foods. Other sources of salmonella include contaminated water and the handling of animals. Symptoms start within six hours to six days from the time of exposure and include fever, diarrhea, nausea, vomiting and stomach pain. Most people recover within 4 to 7 days without treatment, but some cases lead to hospitalization and death. Since the start of President Donald Trump's second term, there have been severe cuts and the federal health services workforce is expected to drop from 82,000 to 62,000, USA TODAY previously reported. Trump argued the cuts are a way to save taxpayers' money, but experts say allocating resources towards food safety is critical. An FDA spokesperson told USA TODAY in an email statement that the agency prioritizes food safety and is committed to working with all stakeholders. 'The layoffs relate to administrative staff positions in the FDA. There has been no impact to operational investigators conducting food safety inspections,' the FDA spokesperson said. Over a decade ago, when annual salmonella numbers were estimated to be lower, the U.S. Department of Agriculture estimated that foodborne illness cost the country $3.7 billion per year, most of which was attributed to premature deaths. Eskin, who previously worked at the U.S. Department of Agriculture overseeing food safety and inspections, said recalls are essential for public health. 'A recall is the last line of defense that you and I have to prevent getting sick,' Eskin said, 'if we're going to a restaurant, or more importantly, going to the grocery store.' Dr. Susan Kansagra, chief medical officer at the Association of State and Territorial Health Officials, said in an email statement that federal funds support a wide range of state-level activities related to foodborne illness, like laboratory testing, case reporting, and guiding providers and the public on prevention and treatment. 'Loss of funding and staffing decreases our national capacity to do these activities and therefore quickly detect and respond to foodborne illness,' Kansagra said.
Yahoo
11 hours ago
- Yahoo
Blueberries Recalled After FDA Issues Highest Warning Over Listeria Contamination
The U.S. Food and Drug Administration has announced a Class I recall for roughly 12,000 pounds of blueberries from Georgia-based Alma Pak International, LLC. A Class I recall is the most severe type of recall possible, reserved only for when there is a reasonable probability that eating a "product will cause serious adverse health consequences or death." While blueberries are generally considered healthy since they're full of essential nutrients, such as Vitamins C and K, manganese, and dietary fiber, the 400 30-pound boxes being recalled might not be as healthy as others. The FDA notes the company received positive test results of Listeria monocytogenes on the recalled berries during routine testing. Listeria, a type of bacteria, can cause listeriosis, symptoms of which include fever, flu-like symptoms, headache, stiff neck, confusion, loss of balance, seizures and more, according to the Centers for Disease Control and Prevention. Symptoms usually occur within two weeks of eating food contaminated with Listeria, the CDC notes. The recalled berries were shipped to one customer in North Carolina and include lot numbers 13325 G1060 and 13325 G 1096. The recall is voluntary, meaning the company initiated it, according to the FDA. Listeria is most likely to harm pregnant women, newborns, older adults, and people with weakened immune systems, but others "rarely become seriously ill," according to the CDC. Listeria can also cause intestinal illness, symptoms of which include diarrhea and vomiting. The CDC recommends that anyone who has a fever and at least one other listeriosis symptom after eating the recalled berries, or anything else that could be contaminated with listeria, should see a doctor. However, for those who have eaten listeria-contaminated food and do not feel sick, most experts believe there is no need for tests or treatment, the CDC notes. Kraft-Heinz also this month recalled roughly 367,812 pounds of turkey over potential listeria contamination, according to the USDA. The news comes during the peak season for blueberries in Georgia, according to Explore Georgia, which is roughly from mid-April through the end of Recalled After FDA Issues Highest Warning Over Listeria Contamination first appeared on Men's Journal on Jul 3, 2025
